1. Home
  2. BBIO
  3. BBIO News

Latest BridgeBio Pharma Inc. (BBIO) News on July 27, 2024

BBIO

MT Newswires

3 days ago

BridgeBio Pharma Names New COO

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
BBIO

GlobeNewswire

4 days ago

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

21 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
BBIO

Insider Monkey

a month ago

BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?

BBIO

MT Newswires

a month ago

BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
BBIO

GlobeNewswire

a month ago

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
BBIO

Investor's Business Daily

2 months ago

BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug

BBIO

MT Newswires

2 months ago

BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment

BridgeBio data show sustained benefit for achondroplasia drug
BBIO

BioPharma Dive

2 months ago

BridgeBio data show sustained benefit for achondroplasia drug

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
BBIO

GlobeNewswire

2 months ago

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
BBIO

GlobeNewswire

2 months ago

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BBIO

GlobeNewswire

2 months ago

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

MT Newswires

2 months ago

UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts
BBIO

Simply Wall St.

2 months ago

Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
BBIO

Simply Wall St.

3 months ago

What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today

BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
BBIO

Simply Wall St.

3 months ago

BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations

BridgeBio Oncology Therapeutics launches with $200m funding
BBIO

Pharmaceutical Technology

3 months ago

BridgeBio Oncology Therapeutics launches with $200m funding

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Shares Decline After Q1 Financial Results

BBIO

Associated Press Finance

3 months ago

BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
BBIO

GlobeNewswire

3 months ago

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
BBIO

GlobeNewswire

3 months ago

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

BridgeBio spinout launches with $200M for KRAS cancer drugs
BBIO

BioPharma Dive

3 months ago

BridgeBio spinout launches with $200M for KRAS cancer drugs

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
BBIO

BioPharma Dive

3 months ago

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BBIO

Zacks

3 months ago

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

4 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BBIO

GlobeNewswire

4 months ago

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
BBIO

TipRanks

4 months ago

TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

4 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
BBIO

Zacks

5 months ago

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

BridgeBio Pharma Announces Proposed Public Offering of Common Stock
BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
BBIO

Investor's Business Daily

5 months ago

BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug

Bayer pays $310M to buy into BridgeBio heart drug
BBIO

BioPharma Dive

5 months ago

Bayer pays $310M to buy into BridgeBio heart drug

BBIO

Reuters

5 months ago

BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe

BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
BBIO

Investor's Business Daily

5 months ago

BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations
BBIO

Simply Wall St.

5 months ago

BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
BBIO

Zacks

5 months ago

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

BBIO

Associated Press Finance

5 months ago

BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials
BBIO

GuruFocus.com

5 months ago

BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
BBIO

Zacks

5 months ago

Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

Alnylam changes to heart drug trial spark doubts, sinking shares
BBIO

BioPharma Dive

5 months ago

Alnylam changes to heart drug trial spark doubts, sinking shares

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

BridgeBio sells partial rights to dwarfism drug for $100M
BBIO

BioPharma Dive

6 months ago

BridgeBio sells partial rights to dwarfism drug for $100M

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

H&R Block Announces Quarterly Cash Dividend
BBIO

GlobeNewswire

6 months ago

H&R Block Announces Quarterly Cash Dividend

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
BBIO

PR Newswire

6 months ago

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

3 Groundbreaking Biotech Stocks to Invest in Now
BBIO

InvestorPlace

6 months ago

3 Groundbreaking Biotech Stocks to Invest in Now

American Express CEO on earnings report card: We will perform in a slowing economy
BBIO

Yahoo Finance

6 months ago

American Express CEO on earnings report card: We will perform in a slowing economy

If EPS Growth Is Important To You, Range Resources (NYSE:RRC) Presents An Opportunity
BBIO

Simply Wall St.

6 months ago

If EPS Growth Is Important To You, Range Resources (NYSE:RRC) Presents An Opportunity

5 Retail Stocks to Buy on Soaring Consumer Confidence
BBIO

Zacks

6 months ago

5 Retail Stocks to Buy on Soaring Consumer Confidence

FAA Puts Limits on Boeing 737 Output, Clears Path for Grounded Jets to Fly
BBIO

The Wall Street Journal

6 months ago

FAA Puts Limits on Boeing 737 Output, Clears Path for Grounded Jets to Fly

Webster Financial (WBS) Dips 2.3% Despite In-Line Q4 Earnings
BBIO

Zacks

6 months ago

Webster Financial (WBS) Dips 2.3% Despite In-Line Q4 Earnings

IAMGOLD (IAG) 2023 Production Meets Its Guidance, Declines Y/Y
BBIO

Zacks

6 months ago

IAMGOLD (IAG) 2023 Production Meets Its Guidance, Declines Y/Y

B2Gold (BTG) Reports Y/Y Rise in '23 Gold Output & Revenues
BBIO

Zacks

6 months ago

B2Gold (BTG) Reports Y/Y Rise in '23 Gold Output & Revenues

BBIO

Thomson Reuters StreetEvents

6 months ago

Q4 2023 Webster Financial Corp Earnings Call

Vail Resorts Achieves 100% Renewable Electricity for Second Consecutive Year & Achieves 2030 Energy-Efficiency Goal Early
BBIO

CNW Group

6 months ago

Vail Resorts Achieves 100% Renewable Electricity for Second Consecutive Year & Achieves 2030 Energy-Efficiency Goal Early

Webster Financial (WBS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
BBIO

Zacks

6 months ago

Webster Financial (WBS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

GXO Schedules Fourth Quarter, Full-Year 2023 Earnings Conference Call for Wednesday, February 14, 2024
BBIO

GlobeNewswire

6 months ago

GXO Schedules Fourth Quarter, Full-Year 2023 Earnings Conference Call for Wednesday, February 14, 2024

Paycom Software (PAYC) Outpaces Stock Market Gains: What You Should Know
BBIO

Zacks

6 months ago

Paycom Software (PAYC) Outpaces Stock Market Gains: What You Should Know

Vail Resorts (MTN) Reports Ski Season Metrics, Stock Up
BBIO

Zacks

6 months ago

Vail Resorts (MTN) Reports Ski Season Metrics, Stock Up

BridgeBio Pharma Inc Director Hannah Valantine Sells 2,915 Shares
BBIO

GuruFocus.com

6 months ago

BridgeBio Pharma Inc Director Hannah Valantine Sells 2,915 Shares

Vail Resorts Warns That Lack of Snow Dented Sales
BBIO

Barrons.com

6 months ago

Vail Resorts Warns That Lack of Snow Dented Sales

First Horizon Corp Reports Full Year 2023 Earnings with Notable Loan Growth
BBIO

GuruFocus.com

6 months ago

First Horizon Corp Reports Full Year 2023 Earnings with Notable Loan Growth

BBIO

Associated Press Finance

6 months ago

First Horizon: Q4 Earnings Snapshot

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

BridgeBio strikes drug royalty deal for cash infusion
BBIO

BioPharma Dive

6 months ago

BridgeBio strikes drug royalty deal for cash infusion

The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market
BBIO

InvestorPlace

6 months ago

The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market

Carvana Announces Top-Selling Electric Vehicles of 2023
BBIO

Business Wire

6 months ago

Carvana Announces Top-Selling Electric Vehicles of 2023

Carvana (CVNA) Dips More Than Broader Market: What You Should Know
BBIO

Zacks

6 months ago

Carvana (CVNA) Dips More Than Broader Market: What You Should Know

3 Growth Stocks to Sell in January Before They Crash and Burn
BBIO

InvestorPlace

6 months ago

3 Growth Stocks to Sell in January Before They Crash and Burn

Forget Annaly Capital: 3 REIT Stocks to Buy Instead
BBIO

Motley Fool

6 months ago

Forget Annaly Capital: 3 REIT Stocks to Buy Instead

16 Best Mid-Cap Growth Stocks To Buy Now
BBIO

Insider Monkey

6 months ago

16 Best Mid-Cap Growth Stocks To Buy Now

GXO Appoints Richard Cawston as Chief Revenue Officer
BBIO

GlobeNewswire

7 months ago

GXO Appoints Richard Cawston as Chief Revenue Officer

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio
BBIO

Zacks

7 months ago

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

GXO Welcomes New Customer Glossier
BBIO

GlobeNewswire

7 months ago

GXO Welcomes New Customer Glossier

Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement
BBIO

GlobeNewswire

7 months ago

Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement

Dolby Laboratories Announces Conference Call and Webcast for Q1 Fiscal 2024 Financial Results
BBIO

PR Newswire

7 months ago

Dolby Laboratories Announces Conference Call and Webcast for Q1 Fiscal 2024 Financial Results

Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions
BBIO

PR Newswire

7 months ago

Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Shockwave Medical Provides Quarterly Earnings Release Dates for 2024
BBIO

GlobeNewswire

7 months ago

Shockwave Medical Provides Quarterly Earnings Release Dates for 2024

Berkshire Buys More Liberty SiriusXM Tracking Stock
BBIO

Barrons.com

7 months ago

Berkshire Buys More Liberty SiriusXM Tracking Stock

CF Industries (CF) Up 17% in 6 Months: What's Driving the Stock?
BBIO

Zacks

7 months ago

CF Industries (CF) Up 17% in 6 Months: What's Driving the Stock?

Here's Why G-III Apparel (GIII) is Poised for Growth in 2024
BBIO

Zacks

7 months ago

Here's Why G-III Apparel (GIII) is Poised for Growth in 2024

BBIO

Business Wire

7 months ago

Stevanato Group to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now
BBIO

Zacks

7 months ago

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now

ShockWave Medical Inc Insider Sells Company Shares
BBIO

GuruFocus.com

7 months ago

ShockWave Medical Inc Insider Sells Company Shares

What Makes Stevanato Group S.p.A. (STVN) a Worthy Stock?
BBIO

Insider Monkey

7 months ago

What Makes Stevanato Group S.p.A. (STVN) a Worthy Stock?

Best Lithium Stocks 2024: 7 to Add to Your Must-Buy List
BBIO

InvestorPlace

7 months ago

Best Lithium Stocks 2024: 7 to Add to Your Must-Buy List

Is Penumbra (PEN) a Good Short Position?
BBIO

Insider Monkey

7 months ago

Is Penumbra (PEN) a Good Short Position?

Share on Social Networks: